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The full-length isoform of matrixmetalloproteinase-2 (FL-MMP-2) plays a role in turnover
of the cardiac extracellular matrix. FL-MMP-2 is also present intracellularly in association
with sarcomeres and, in the setting of oxidative stress, cleaves myofilament proteins
with resultant impaired contractility. Recently, a novel N-terminal truncated MMP-2
isoform (NTT-MMP-2) generated during oxidative stress was identified and shown to
induce severe systolic failure; however, the injury mechanisms remained unclear. In
this study, cardiac-specific NTT-MMP-2 transgenic mice were used to determine the
physiological effects of NTT-MMP-2 on: force development of intact myocardium; the
function of cardiac myofilaments in demembranated myocardium; and on intracellular
Ca2+ transients in isolated myocytes. We related the contractile defects arising from
NTT-MMP-2 expression to the known intracellular locations of NTT-MMP-2 determined
using immunohistochemistry. Comparison was made with the pathophysiology arising
from cardiac-specific FL-MMP-2 transgenic mice. Consistent with previous studies,
FL-MMP-2 was localized to myofilaments, while NTT-MMP-2 was concentrated within
subsarcolemmal mitochondria and to sites in register with the Z-line. NTT-MMP-2
expression caused a 50% reduction of force development by intact myocardium. However,
NTT-MMP-2 expression did not reduce myofilament force development, consistent with
the lack of NTT-MMP-2 localization to myofilaments. NTT-MMP-2 expression caused a
50% reduction in the amplitude of Ca2+ transients, indicating impaired activation.
Conclusions: Unlike FL-MMP-2, NTT-MMP-2 does not mediate myofilament damage.
Instead, NTT-MMP-2 causes impaired myocyte activation, which may involve effects due
to localization in mitochondria and/or to transverse tubules affecting Ca2+ transients. Thus,
FL-MMP-2 and NTT-MMP-2 have discrete intracellular locations and mediate different
intracellular damage to cardiac myocytes.
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INTRODUCTION
While the overall mortality rates for acute myocardial infarc-
tion have decreased in recent years due to the advent of more
effective acute interventions, the incidence of dysfunctional post-
myocardial ventricular remodeling continues to increase. The
most serious complication of post-infarction remodeling is con-
gestive heart failure, which has become one of the leading
causes of death in ischemic cardiac disease. Recent experimen-
tal and clinical evidence has underscored a critical role for
matrix metalloproteinase-2 (MMP-2) in ischemic cardiac dis-
ease, including post-infarction ventricular remodeling (Alfonso-
Jaume et al., 2006; Mukherjee et al., 2006; Bergman et al.,
2007; Zhou et al., 2007; Nilsson et al., 2011; Lovett et al., 2012,
2013; Cogni et al., 2013). Our current gaps in knowledge are
substantial and relate to an incomplete understanding of the
multiple pathophysiologic roles of MMP-2 in post-infarction
remodeling.
MMP-2 affects multiple factors involved in ischemic ven-
tricular remodeling, inflammation and cardiomyocyte apoptosis.
MMP-2 was originally investigated as the full-length secreted
enzyme involved in the turnover of the extracellular matrix.
However, recent studies have defined a pool of intracellularMMP-
2 arising from a fraction of full-length MMP-2 (FL-MMP-2) that
escapes from the secretory pathway and, in the setting of redox
stress, causes intracellular damage to the myofilaments in car-
diomyocytes (Wang et al., 2002; Sawicki et al., 2005; Schulz, 2007;
Lovett et al., 2012, 2013).
Under pathophysiological conditions, MMP-2 is known to be
associated with cardiac dysfunction. To determine the role of
MMP-2 in the absence of superimposed injury, we previously
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used cardiac-specific transgenic mice that expressed constitutively
active FL- MMP-2 (Wang et al., 2006; Bergman et al., 2007). We
reported that FL-MMP-2 expression resulted in a 50% reduction
of contractile force of electrically stimulated cardiac trabeculae.
Furthermore, impaired force development was associated with a
50% reduction of myofilament force development assessed using
demembranated myocardium exposed to activating solutions
(Wang et al., 2006). These studies suggest that, in the absence of
superimposed injury, FL-MMP-2 impairs myocardial contraction
by damaging the myofilaments. Consistent with this, FL-MMP-2
localizes to the myofilaments (Bergman et al., 2007) and recent
studies demonstrate that intracellular FL-MMP-2 cleaves sev-
eral myofilament-associated proteins, including troponin I, titin,
α-actinin and myosin essential light chain (Ali et al., 2011).
We recently identified a second intracellular MMP-2 isoform,
N-terminal truncated MMP-2 (NTT-MMP-2) that is generated
by redox stress-mediated activation of an alternate promoter in
the first intron of the MMP-2 gene (Lovett et al., 2012). Oxidative
stress-mediated generation of NTT-MMP-2 may contribute to
progressive cardiac dysfunction in the setting of ischemia (Lovett
et al., 2012). Translation of the NTT-MMP-2 transcript is ini-
tiated at Methionine77, resulting in an N-terminal truncated
MMP-2 protein lacking the secretory sequence and the inhibitory
prodomain. Thus, the NTT-MMP-2 protein remains intracellu-
lar and is enzymatically active. In-vitro cell fractionation studies
localized the NTT-MMP-2 isoform to cytosolic and mitochon-
drial fractions (Lovett et al., 2012). Within the context of the
intact heart, the NTT-MMP-2 isoform was primarily localized to
mitochondria and also localized to perpendicular arrays across
the long axis of individual cardiomyocytes (Lovett et al., 2013).
In addition to activation of NTT-MMP-2, ischemic cardiac injury
involves activation of multiple other factors. Therefore, for the
current study, to focus only on the physiological effects medi-
ated by NTT-MMP-2, we used transgenic expression of NTT-
MMP-2 in mouse hearts. Cardiac-specific transgenic expression
of the NTT-MMP-2 isoform induced severe systolic failure; how-
ever, the injury mechanisms involved were unclear (Lovett et al.,
2013). Therefore, the goal of this study was to investigate the
mechanisms of NTT-MMP-2-mediated cardiac systolic failure.
We report that the NTT-MMP-2 isoform directly impairs car-
diomyocyte contractility by affecting calcium handling. Thus, the
FL-MMP-2 and NTT-MMP-2 isoforms contribute differently to
cardiac contractile dysfunction.
MATERIALS AND METHODS
TRANSGENIC MICE
This institution is accredited by the American Association for
the Accreditation of Laboratory Animal Care (Institutional PHS
Assurance Number is A3476-01). The investigation was approved
by the Animal Care and Use Subcommittee (IACUC) of the San
Francisco Veterans Affairs Medical Center (protocol 09-053-03)
and conformed to the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health (Revised
2011).
Cardiac-specific transgenic mice expressing the NTT-MMP-2
isoform were generated in the CD-1 background as previously
described (Lovett et al., 2013). Four to five month old transgenic
and littermate controls were used. Cardiac-specific transgenic
mice expressing the FL-MMP-2 isoform were generated and char-
acterized as reported (Bergman et al., 2007). Four to five month
old transgenic mice and littermate controls were used.
IMMUNOHISTOLOGICAL DETECTION OF MMP-2 ISOFORMS
For localization of the c-myc-tagged FL-MMP-2 transgene,
paraformaldehyde-fixed ventricular sections were incubated with
murine monoclonal anti-c-myc (9E11, Abcam, Cambridge, MA),
followed by the M.O.M. kit (Vector, Burlingame, CA) and
development with VIP purple substrate (Vector) as previously
described (Bergman et al., 2007).
Intracellular localization of the NTT-MMP-2-EGFP transgene
was performed on deparaffinized sections following citrate anti-
gen retrieval (Vector) using a 1:1000 dilution of rabbit polyclonal
anti-GFP (Abcam, Ab6556) for 4 h, followed by incubation with
1:2000 biotinylated goat-anti-rabbit IgG. Histochemical devel-
opment with diaminobenzidine-Ni+2 (DAB- Ni+2, Vector) was
restricted to 3min to limit reaction product migration, followed
by a hematoxylin counterstain. Images were digitally captured
at high resolution (4000 dpi) using a Zeiss Nomarksy optics
microscope. A dense focus of DAB- Ni+2 reaction product in
the transgenic image was sampled in Adobe Photoshop CS4. Foci
with similar pixel densities were converted to a fluorescent pseu-
docolor using the Image Adjust/Change Color tool to enhance
contrast with background DAB- Ni+2 staining. The wild type
control images were processed simultaneously in an identical
fashion.
CONTRACTION OF INTACT MYOCARDIUM
Mice were deeply anesthetized with pentobarbital (100mg/kg
i.p.) mixed with heparin (100 U). Hearts were removed from
anesthetized mice and flushed with modified Krebs-Henseleit, as
previously described (Wang et al., 2006). A free-running trabec-
ula was dissected from the right ventricle. For NTT-MMP-2 mice
and wild type controls, the width, thickness and cross-sectional
area of trabeculae were: 148 ± 62μm, 79 ± 16μm, 0.012 ±
0.007mm2, n = 4; and 174 ± 11μm, 123 ± 18μm, 0.017 ±
0.003mm2, n = 4; there was not a significant difference in these
values between NTT-MMP-2 and wild type (P > 0.05, ANOVA).
Trabeculae were placed in a muscle chamber and mounted to a
force transducer, and sarcomere length set to 2.1μm. Trabeculae
were superfused with Krebs-Henseleit solution at 22◦C and field
stimulated (0.5Hz pacing frequency and voltage 1.5 × threshold)
(Wang et al., 2006).
ASSESSMENT OF MYOFILAMENT CONTRACTION
After recording electrically stimulated contractions, these same
trabeculae were demembranated using 1% Triton X-100, and
in-vitro myofilament function was assessed using steady state
contractions at various bath [Ca2+] as previously described
(Wang et al., 2006). The relationship between steady state force
(F) and [Ca2+] was fit to the Hill equation: F = Fmax×
[Ca2+]nH/([Ca2+]nH + EC50nH), where Fmax is the maximum
Ca2+-activated force, EC50 is the [Ca2+] at which F is 50%
of Fmax, and nH is Hill coefficient reflecting the slope of the
Ca2+-force relationship at EC50.
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MEASUREMENT OF Ca2+ TRANSIENTS
Myocyte Ca2+ transients were recorded using from the flu-
orescence of Fura-2 as we recently described (Chu et al.,
2013). Briefly, mice were deeply anesthetized with pentobar-
bital (100mg/kg i.p.) mixed with heparin (100 U). Hearts
were rapidly removed and immersed in ice-cold arrest solu-
tion (in mM: NaCl 120, KCl 30, CaCl2 0.1). Myocytes were
isolated by enzymatic digestion of the heart by retrograde per-
fusion of the aorta with collagenase solution (O’Connell et al.,
2007). After collagenase treatment, the heart was placed in a
“stop buffer” to halt enzymatic digestion (O’Connell et al.,
2007). The heart was placed in 10mL of stop buffer and gen-
tly teased with fine forceps followed by repeated pipetting to
release the cells. The cell isolation buffers contained 10mM BDM
(2,3-Butanedione monoxime) to prevent cell contraction. Cells
were used within 4 h of isolation. We studied 38 cells from 9
animals.
Myocytes were loaded with the Ca2+ indicator Fura-2 by expo-
sure to 1μM Fura-2-AM for 20min. After washing, myocytes
were equilibrated for 20min to allow for de-esterification of the
indicator and used within 1.5 h. after completion of the loading
protocol.
Myocytes were superfused in a small glass-floored chamber
with Krebs Henseleit solution containing (in mM): NaCl, 112;
KC1, 5; MgCl2, 1.2; glucose, 10; NaHCO3, 24; Na2SO4, 1.2;
NaH2PO4, 2.0; and CaCl2, 1. The perfusate was oxygenated with
95% O2/5% CO2 to give a pH of 7.4 at 22◦C. The chamber
was mounted on an inverted Nikon Diaphot microscope and
cells visualized at x40 magnification. Cells were electrically stim-
ulated with 4ms square wave pulses, at a frequency of 0.5Hz.
Cell contraction and Fura-2 fluorescence were monitored using
an IonOptix Hyperswitch system (Milton, MA). Cell contrac-
tion was computed by monitoring changes in muscle sarcomere
length measured from the myocyte striation spacing. Fura-2 flu-
orescence at an emission wavelength of 510 nm was measured,
with the excitation alternated between 340 and 380 nm at a
frequency of 240Hz. Background autofluorescence at each wave-
length was subtracted before computing the Fura-2 fluorescence
ratio.
STATISTICAL ANALYSIS
Data presented as mean ± SE. Statistical comparison used
unpaired Student’s t-test, and Two-Way ANOVA with repeated
measures followed by the Bonferroni’s post-hoc test to compare
between groups. The significance level was set at P < 0.05.
RESULTS
DISTINCT LOCALIZATION OF NTT-MMP-2 vs. FL-MMP-2
Figure 1 shows immunohistochemical staining of ventricular
myocardium from NTT-MMP-2 transgenic mice. Punctate stain-
ing for eGFP-tagged NTT-MMP-2 transgene is concentrated
within subsarcolemmal mitochondria (Figure 1B) consistent
with our previous report (Lovett et al., 2013). In addition,
punctate staining for the NTT-MMP-2 transgene is localized
to discrete clusters that are in register with the Z-line of the
sarcomere (Figure 1C), which may reflect structures associ-
ated with transverse tubules. This is consistent with our previ-
ous finding of NTT-MMP-2 localized to perpendicular arrays
across the long axis of individual cardiomyocytes (Lovett et al.,
2013). Myocardium from wild type mice did not show specific
localization of signal for NTT-MMP-2 (Figure 1A).
Figure 2 shows immunohistochemical staining of ventricular
myocardium from FL-MMP-2 transgenic mice. Consistent with
our previous report (Bergman et al., 2007), a prominent stri-
ated pattern is evident in the stained section consistent with a
sarcomeric localization of the c-myc tagged FL-MMP-2 trans-
gene (Figure 2B). Ventricular myocardium from wild type mice
did not show significant staining for the FL-MMP-2 transgene
(Figure 2A).
These findings confirm that the NTT-MMP-2 and FL-MMP-2
isoforms were localized to distinct intracellular compartments.
TRANSGENIC NTT-MMP-2 EXPRESSION REDUCED MYOCARDIAL
FORCE DEVELOPMENT
Figure 3A shows electrically stimulated force development of
myocardium from wild type and NTT-MMP-2 transgenic hearts.
Extracellular bath [Ca2+] was varied to assess force development
over the full range of cardiac muscle activation. Figure 3A shows
considerably lower force development by intact myocardium
FIGURE 1 | Expression of NTT-MMP-2 in transgenic hearts.
Immunohistochemical staining for the eGFP epitope tag present on the
NTT-MMP-2 transgene. Pseudo-color enhanced immunohistochemistry of
wild type (A) and transgenic (B,C) ventricular sections (400× original
magnification). NTT-MMP-2 is present within mitochondria, particularly within
subsarcolemmal mitochondria (indicated by arrows in B) and localizes to
clusters in register with the Z-line (arrow in C). No NTT-MMP-2 staining
pattern was evident in wild type hearts. Intracellular NTT is much less
abundant that the FL-MMP-2 isoform, therefore, pseudo-color enhancement
was used to improve contrast and to visualize the subcellular localization.
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FIGURE 2 | Expression of FL-MMP-2 in transgenic hearts.
Immunohistochemical staining for the c-myc epitope tag of the FL-MMP-2
transgenic using peroxidase stain for wild type (A) and transgenic (B)
ventricular sections (400× original magnification). The staining in a regular
banding pattern (indicated by arrows in B) is consistent with a sarcomeric
localization. No staining was evident in wild type.
from NTT-MMP-2 transgenic mice compared to wild type mice,
at the higher levels of activation. Diastolic force levels were low,
with no difference in diastolic force level between NTT-MMP-2
transgenic vs. wild type myocardium (0.79 ± 0.25 vs. 0.76 ± 0.22
mN/mm2, P > 0.05).
Thus, both transgenic NTT-MMP-2 expression, and trans-
genic FL-MMP-2 expression (Wang et al., 2006) cause similar
reductions of force development by intact myocardium.
TRANSGENIC NTT-MMP-2 EXPRESSION DID NOT AFFECT
MYOFILAMENT FORCE DEVELOPMENT
These same trabeculae were chemically skinned and exposed to
activating solutions with various levels of free [Ca2+] to mea-
sure myofilament force, separate from influences from the muscle
activation system or muscle energy stores. Figure 3B shows that
myofilament force development by trabeculae from NTT-MMP-
2 hearts was indistinguishable from that of trabeculae from wild
type hearts. Furthermore, Hill parameters calculated by fitting
myofilament force-Ca2+ relationships to the Hill equation were
not different between NTT-MMP-2 and wild type (Figure 4).
The data from skinned myocardium suggests that the
decreased force development of intact NTT-MMP-2 trabecu-
lae (Figure 3A) did not involve intrinsically impaired myofila-
ment function. This conclusion is consistent with the histology
data showing that NTT-MMP-2 did not localize to the myofil-
aments (Figure 2). The absence of an effect of NTT-MMP-2 on
myofilament force suggests that NTT-MMP-2 reduced the active
force development of intact muscle by impairing other processes
required for force generation such as impaired muscle activation.
These findings with NTT-MMP-2 expression differ consid-
erably from those obtained with FL-MMP-2 expression, which
was associated with markedly reduced myofilament force devel-
opment (Wang et al., 2006). This suggests that there are distinctly
different mechanisms involved in the reductions of myocardial
force mediated by NTT-MMP expression vs. FL-MMP-2 expres-
sion. With FL-MMP-2 reducing myofilament contraction, but
NTT-MMP-2 not affecting myofilament contraction.
FIGURE 3 | (A) Relationship between developed force vs. bath [Ca2+] for
electrically stimulated intact trabeculae. Trabeculae from transgenic (Tg)
NTT-MMP-2 mice developed less force with raised bath [Ca2+] compared to
wild type controls (P < 0.001, ANOVA; mean ± SE, n = 4/group,
∗∗P < 0.01, ∗∗∗∗P < 0.0001). (B) Relationship between steady-state force
development and [Ca2+] for skinned trabeculae (error bars were less than
the symbol size). There was no statistical difference in myofilament force
development of trabeculae from wild type vs. Tg NTT-MMP-2 mice
(Two-Way ANOVA), thus, expression of NTT-MMP-2 did not reduce
myofilament force in skinned myocardium. Lines show fitting of the pooled
data to the Hill equation.
TRANSGENIC NTT-MMP-2 EXPRESSION REDUCED MYOCYTE Ca2+
TRANSIENTS
We recorded Ca2+ transients in electrically stimulated single
cardiac myocytes using the fluorescent Ca2+ indicator Fura-2.
Figure 5 shows Ca2+ transients recorded from single myocytes
from wild type or NTT-MMP-2 transgenic hearts. The myocyte
Ca2+ transient amplitude was appreciably reduced by transgenic
NTT-MMP-2 expression compared to wild type. The pooled
data show that the amplitude of the Ca2+ transient was reduced
approximately 50% in NTT-MMP-2 myocytes vs. wild type
myocytes (Figure 6A). The reduced Ca2+ transient caused by
NTT-MMP-2 expression was due to a reduced systolic Ca2+ level
without appreciable effect on diastolic Ca2+ level. Consistent with
a similar diastolic Ca2+ level, the diastolic sarcomere length was
identical in NTT-MMP-2 expressing myocytes (1.80 ± 0.01μm,
n = 16) vs. wild type myocytes (1.80 ± 0.01μm, n = 22). The
pooled data show that for myocytes expressing NTT-MMP-2, the
amplitude of the Ca2+ transient and contractions were reduced
compared to myocytes from wild type hearts (Figure 6B).
NTT-MMP-2 expression did not have an appreciable effect on
the dynamics of contraction and relaxation of cardiac myocytes.
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FIGURE 4 | Pooled data of Hill parameters derived from fitting the
force-Ca2+ relationship for individual experiments to the Hill equation.
(A) Fmax (maximum Ca2+-activated force); (B) Ca2+ sensitivity EC50 ([Ca2+]
at 50% Fmax); (C) Hill coefficient nH (slope of Ca2+-force relationship at
EC50). For all Hill parameters, no statistical differences were found between
NTT-MMP-2 vs. wild type (P ns, Two-Way ANOVA; mean ± SE,
n = 4/group).
For NTT-MMP-2 mice vs. wild type controls, the time to peak
contraction and time to 50% relaxation were: 92± 8ms, and 90±
7ms, n = 19; vs. 95 ± 5ms and 100 ± 10ms, n = 22; there was
not a significant difference in these values between NTT-MMP-2
and wild type (P > 0.05, ANOVA).
In summary, the data show that unlike FL-MMP-2, NTT-
MMP-2 was not localized with the myofilaments, and did not
cause impaired myofilament force development. NTT-MMP-2
caused impaired muscle activation, evidenced by decreased
Ca2+ transients.
DISCUSSION
The major findings of this study were that transgenic expres-
sion of NTT-MMP-2 impaired myocardial contraction, and
that impaired contraction did not involve decreased myofil-
ament force. Instead, NTT-MMP-2 expression was associated
with decreased calcium transients. These findings are in con-
trast to our previous findings that FL-MMP-2 expression
resulted in decreased myocardial contraction that did involve
FIGURE 5 | Reduced Ca2+ transients with NTT-MMP-2 expression.
Original records of Fura-2 Ca2+ transients recorded from electrically
stimulated single cardiac myocytes. Compared to wild type controls (A),
NTT-MMP-2 transgenic cells had reduced Ca2+ transient amplitude (B).
decreasedmyofilament force. Thus, the present study expands our
understanding of the pathobiology of MMP-2 by demonstrating
that two distinct isoforms ofMMP-2 impair different intracellular
processes.
Underscoring the disease relevance of MMP-2-mediated
cardiac injury, studies in humans have implicated MMP-2 in
LV dysfunction and dysfunctional remodeling after myocardial
infarction (Nilsson et al., 2011; Cogni et al., 2013). Previous stud-
ies report decreased in-vivo function due to transgenic expression
of FL-MMP-2 (Bergman et al., 2007) or NTT-MMP-2 (Lovett
et al., 2013). Moreover, hemodynamic function measured in-vitro
after ischemic injury showed reduced left ventricular developed
pressure with transgenic expression of FL-MMP-2 (Zhou et al.,
2007) or NTT-MMP-2 (Lovett et al., 2013).
FL-MMP-2 was confirmed to localize to the myofilaments
(Bergman et al., 2007), consistent with a known effect of FL-
MMP-2 causing myofilament injury (Wang et al., 2006). In con-
trast, NTT-MMP-2 did not localize to myofilaments, and did not
cause myofilament injury. Previously, NTT-MMP-2 was found
to localize to mitochondria primarily within the subsarcolemmal
space, and to perpendicular arrays across the long axis of indi-
vidual cardiomyocytes (Lovett et al., 2013). The present study
confirmed this and found that NTT-MMP-2 appeared within
clusters along the Z-line.
These studies used transgenic NTT-MMP-2 mice at 4–5
months of age. At this age these mice have normal cardiac
histology. Physiologic characterization of these mice with serial
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FIGURE 6 | Pooled data from cells from Tg NTT-MMP-2 mice and wild
type. (A) Cells from Tg NTT-MMP-2 hearts had lower systolic Ca2+ levels
than cells from wild type (∗∗P < 0.01). (B) Pooled data (mean ± SE) for
contraction amplitude vs. Ca2+ transient amplitude for cells from Tg
NTT-MMP-2 hearts and wild type [n = 16.22 cells/group from wild type
mice (n = 5) and NTT-MMP-2 expressing mice (n = 4)]. Cells from Tg
NTT-MMP-2 hearts had smaller Ca2+ transients and contractions compared
to wild type. There was a significant linear relation between contraction vs.
Ca2+ transient amplitude (P < 0.001).
echocardiography revealed normal functional parameters other
than a small decrease in left ventricular ejection fraction (Lovett
et al., 2013). Thus, the impaired contractile function defined in
the current study precedes the development of severe systolic
dysfunction and is not a consequence thereof.
FL-MMP-2 is known to be involved in regulation of the car-
diac extracellular matrix (Spinale, 2007), and to contribute to
dysfunctional extracellular remodeling in the setting of myocar-
dial infarction (Hayashidani et al., 2003). However, recent studies
have recognized that FL-MMP-2 is also an intracellular protease
(Schulz, 2007), with almost 40% of newly synthesized FL-MMP-
2 retained in the cytosol due to an inefficient secretory signal
(Ali et al., 2012). In the setting of oxidative stress, intracellular
FL-MMP-2 is activated by release of the inhibitory prodomain,
leading to FL-MMP-2-mediated cleavage of sarcomeric proteins
with resultant contractile dysfunction (Schulz, 2007).
NTT-MMP-2 is a novel intracellular MMP-2 isoform gen-
erated by oxidative stress-mediated activation of an alternate
promoter in the first intron of the MMP-2 gene (Lovett
et al., 2012, 2013). NTT-MMP-2 lacks the secretory peptide
and the inhibitory prodomain and thus is enzymatically active
and acts exclusively on intracellular targets. Like FL-MMP-2,
cardiac-specific NTT-MMP-2 transgene expression also leads to
systolic failure (Lovett et al., 2013). But the mechanisms involved
have been unclear.
In contrast to FL-MMP-2, which localizes to the myofilaments,
NTT-MMP-2 is not localized to the myofilaments. The absence of
NTT-MMP-2 on the myofilaments is consistent with our find-
ing that myofilament force was not impaired in NTT-MMP-2
transgenic hearts. Intact myocardium from hearts with transgenic
expression of NTT-MMP-2 had a 50% reduction in electrically
stimulated myocardial force. Therefore, the reduced force of
intact myocardium was not due to a reduction of intrinsic myofil-
ament force. Instead, we found that NTT-MMP-2 was localized to
subsarcolemmal mitochondria and to clusters that were in regis-
ter with the Z-line of the sarcomere. NTT-MMP-2 localized to
the Z-line could reflect association with the transverse tubule
(t-tubule), which is critically involved in excitation-contraction
coupling. Disruptions of t-tubular structure and function have
been implicated with impaired myocyte activation in heart failure
(Cannell et al., 2006; Orchard and Brette, 2008). NTT-MMP-
2 effects on the t-tubule might be consistent with our finding
that NTT-MMP-2 expression substantially impaired the ampli-
tude of the Ca2+ transient in isolated myocytes. Impaired mus-
cle activation with decreased Ca2+ transients may play a role
in the reduced myocardial contraction caused by NTT-MMP-2
expression.
A prominent ultrastructural feature of the NTT-MMP-2 trans-
genic mice was the presence of swollen mitochondria with loss of
organized cristae (Lovett et al., 2013). Thesemorphologic features
are characteristic of the opening of the mitochondrial perme-
ability transition pore (MTP) (Buki et al., 2000). MTP opening
is associated with enhanced oxidative stress due to uncoupling
of the mitochondrial electron transport chain (Halestrap and
Pasdois, 2009). Cardiac oxidant stress has multiple deleterious
effects on calcium and sodium handling, which may also con-
tribute to impaired contraction and Ca2+ transients associated
with NTT-MMP-2 expression (Sag et al., 2013).
LIMITATIONS
We studied contracting cells and trabeculae, and demembranated
trabeculae at 22◦C. While demembranated trabeculae are more
stable for study at low temperature, nevertheless, tempera-
ture is known to affect contraction and relaxation properties
(Janssen et al., 2002). Although wild type and transgenic groups
were studied under the same conditions, caution is needed
for extrapolating from the results of this study to the intact
heart. Furthermore, to explore the full range of muscle activa-
tion, we used high bath Ca2+ levels in both intact and skinned
myocardium. High Ca2+ levels and maximal levels of activa-
tion are not achieved in-vivo and therefore, caution is needed
for extrapolating from these experimental conditions. To under-
stand the basis of decreased Ca2+ transients with transgenic
NTT-MMP-2 expression, mechanistic studies are needed to inves-
tigate the roles of mitochondria and Ca2+-handling systems that
might be affected by NTT-MMP-2. Finally, as NTT-MMP-2 is
activated by redox stress, greater understanding of the effect
of NTT-MMP-2 expression in the context of redox stress is
needed.
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CONCLUSION
Two discreteMMP-2 isoforms have distinctive pathophysiological
mechanisms that impair cardiomyocyte contractility. FL-MMP-2
was previously reported to injure the myofilaments, in con-
trast, the current study found NTT-MMP-2 does not injure the
myofilaments but impairs muscle activation involving reduced
Ca2+ transients.
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